Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jaguar Health, Inc. (NASDAQ: JAGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its capital markets activity and material agreements. Jaguar is a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals, and its filings provide insight into how it finances and supports these programs.
Recent Form 8-K filings describe a range of transactions, including secured and unsecured promissory notes, royalty interest agreements and amendments, PIPE financings involving Series N Perpetual Preferred Stock and common stock with pre-funded warrants, and privately negotiated exchanges of preferred stock for common shares and pre-funded warrants. Other 8-Ks outline at-the-market offering amendments, conditional approval-related developments for Canalevia-CA1, and note purchase agreements backed by deposit account control arrangements and subsidiary guarantees.
Jaguar’s proxy materials, such as definitive proxy statements on Schedule 14A, detail stockholder proposals to approve share issuances under Nasdaq Listing Rule 5635(d), including common stock issuable upon exchange of Series L, Series M, and Series N preferred stock and upon conversion of certain convertible promissory notes and related warrants. These documents also explain voting rights, voting caps for preferred series, and the structure of special and annual meetings.
On this page, users can review Jaguar’s 10-K and 10-Q reports (when available) for broader business and risk disclosures, while Form 4 and related ownership filings provide visibility into insider equity transactions. Stock Titan enhances these filings with AI-powered summaries that highlight key terms in complex documents, such as interest rates, maturity dates, collateral arrangements, voting provisions, and share issuance conditions. Real-time updates from EDGAR ensure that new Jaguar Health filings, including 8-Ks announcing material events, are quickly accessible with plain-language explanations.
Jonathan S. Wolin, Chief of Staff, Chief Compliance Officer and General Counsel of Jaguar Health (JAGX), reported significant changes in derivative securities holdings on June 24, 2025:
- Disposed of an existing 6% convertible promissory note due 6/30/2025 (Original Note) in exchange for a new note through an issuer exchange offer
- Received a new 6% convertible promissory note maturing 1/30/2026, convertible into 9,462 shares of common stock at $5.555 per share
- As inducement, received a warrant to purchase 18,262 shares at $2.70 per share, exercisable upon stockholder approval and expiring after 18 months
This transaction represents a restructuring of the executive's convertible debt holdings, extending the maturity date by 7 months and providing additional equity exposure through warrants. The new note's conversion terms and warrant structure suggest potential upside participation in the company's future performance.
Lisa A. Conte, CEO, President and Director of Jaguar Health (JAGX), reported significant changes in derivative securities holdings on June 24, 2025. The transactions involved restructuring of convertible debt and issuance of new warrants:
- Disposed of original 6% convertible promissory note (9,000 shares at $5.555 conversion price) maturing June 30, 2025
- Acquired new 6% convertible promissory note (9,462 shares at $5.555 conversion price) maturing January 30, 2026
- Received warrant to purchase 18,262 common shares at $2.70 exercise price, expiring December 24, 2026
The exchange was part of an issuer exchange offer, extending the maturity of the convertible debt by 7 months. The warrant was issued as an inducement and becomes exercisable upon stockholder approval. The transaction indicates potential debt restructuring efforts by the company while providing the executive with additional equity participation opportunities.
Jaguar Health, Inc. (Nasdaq: JAGX) filed a Form S-3 shelf registration statement dated June 20, 2025. The filing registers up to 507,390 shares of common stock for resale by existing security holders: (i) 492,612 shares underlying outstanding common warrants and (ii) 14,778 shares underlying placement-agent warrants issued in a May 22, 2025 private placement.
Key warrant terms:
- Common Warrants: exercisable immediately at $5.84 per share; expiration is the earlier of 24 months from issuance, a fundamental transaction, or a liquidation event.
- Placement-Agent Warrants: exercisable immediately at $7.6125 per share; same maturity framework as the common warrants.
The company qualifies as a non-accelerated filer and a smaller reporting company; it is not an emerging-growth company. Jaguar will receive no proceeds from stockholder resales, but will obtain cash only upon warrant exercise. The last reported Nasdaq closing price on June 18, 2025 was $2.78—well below both exercise prices—so immediate exercise is unlikely absent a price increase.
The prospectus highlights the company’s commercial focus on plant-based gastrointestinal therapeutics, including crofelemer (Phase 3 OnTarget study) and the recently in-licensed Gelclair product. Investors are directed to the company’s Form 10-K for the year ended December 31, 2024 (filed March 31 and amended April 15, 2025) for a full risk discussion.
Use of proceeds: none from resales; potential, unspecified proceeds from future cash exercises of the warrants.